The role of DNA microarrays in the evaluation of fetal death

Uma M. Reddy, Grier P. Page, George Saade

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Fetal death occurs in 15% of clinically recognized pregnancies. Cytogenetic abnormalities are present in 50% of spontaneous abortions (fetal deaths<20weeks) whereas the rate is 6% to 13% for stillbirths (fetal deaths≥20weeks). Microarray has been demonstrated to increase the diagnosis of genetic abnormalities by providing coverage of the entire genome at a higher density, detecting as small as 50 to 100kb deletions or duplications, known as copy number changes. Microarray is particularly suited for evaluation of fetal death because DNA can still be analyzed in macerated fetuses and nonviable tissue, two situations where culturing and karyotyping is known to have low yield. Microarray has already proven successful in providing additional genetic information beyond karyotype in spontaneous abortion. The few studies on the use of microarray in stillbirth evaluation have been promising, demonstrating an increase in the diagnosis of clinically relevant genetic abnormalities when compared with karyotype. As the cost and technology improve, microarray may ultimately become the first line screen for genetic abnormalities in stillbirth. The accurate diagnosis of a genetic abnormality as the cause for fetal death may provide closure for families, prevent unnecessary treatments, and enable clinicians to more accurately counsel and manage subsequent pregnancies.

Original languageEnglish (US)
Pages (from-to)371-375
Number of pages5
JournalPrenatal Diagnosis
Volume32
Issue number4
DOIs
StatePublished - Apr 2012

Fingerprint

Fetal Death
Oligonucleotide Array Sequence Analysis
Stillbirth
Spontaneous Abortion
Karyotype
Karyotyping
Pregnancy
Chromosome Aberrations
Cause of Death
Fetus
Genome
Technology
Costs and Cost Analysis
DNA

Keywords

  • Array CGH
  • Fetal death
  • Fetal demise
  • General cytogenetics
  • Spontaneous abortion
  • Stillbirth

ASJC Scopus subject areas

  • Genetics(clinical)
  • Obstetrics and Gynecology

Cite this

The role of DNA microarrays in the evaluation of fetal death. / Reddy, Uma M.; Page, Grier P.; Saade, George.

In: Prenatal Diagnosis, Vol. 32, No. 4, 04.2012, p. 371-375.

Research output: Contribution to journalArticle

Reddy, Uma M. ; Page, Grier P. ; Saade, George. / The role of DNA microarrays in the evaluation of fetal death. In: Prenatal Diagnosis. 2012 ; Vol. 32, No. 4. pp. 371-375.
@article{1fde5b42f73c46b1808097d8fbdb8c58,
title = "The role of DNA microarrays in the evaluation of fetal death",
abstract = "Fetal death occurs in 15{\%} of clinically recognized pregnancies. Cytogenetic abnormalities are present in 50{\%} of spontaneous abortions (fetal deaths<20weeks) whereas the rate is 6{\%} to 13{\%} for stillbirths (fetal deaths≥20weeks). Microarray has been demonstrated to increase the diagnosis of genetic abnormalities by providing coverage of the entire genome at a higher density, detecting as small as 50 to 100kb deletions or duplications, known as copy number changes. Microarray is particularly suited for evaluation of fetal death because DNA can still be analyzed in macerated fetuses and nonviable tissue, two situations where culturing and karyotyping is known to have low yield. Microarray has already proven successful in providing additional genetic information beyond karyotype in spontaneous abortion. The few studies on the use of microarray in stillbirth evaluation have been promising, demonstrating an increase in the diagnosis of clinically relevant genetic abnormalities when compared with karyotype. As the cost and technology improve, microarray may ultimately become the first line screen for genetic abnormalities in stillbirth. The accurate diagnosis of a genetic abnormality as the cause for fetal death may provide closure for families, prevent unnecessary treatments, and enable clinicians to more accurately counsel and manage subsequent pregnancies.",
keywords = "Array CGH, Fetal death, Fetal demise, General cytogenetics, Spontaneous abortion, Stillbirth",
author = "Reddy, {Uma M.} and Page, {Grier P.} and George Saade",
year = "2012",
month = "4",
doi = "10.1002/pd.3825",
language = "English (US)",
volume = "32",
pages = "371--375",
journal = "Prenatal Diagnosis",
issn = "0197-3851",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - The role of DNA microarrays in the evaluation of fetal death

AU - Reddy, Uma M.

AU - Page, Grier P.

AU - Saade, George

PY - 2012/4

Y1 - 2012/4

N2 - Fetal death occurs in 15% of clinically recognized pregnancies. Cytogenetic abnormalities are present in 50% of spontaneous abortions (fetal deaths<20weeks) whereas the rate is 6% to 13% for stillbirths (fetal deaths≥20weeks). Microarray has been demonstrated to increase the diagnosis of genetic abnormalities by providing coverage of the entire genome at a higher density, detecting as small as 50 to 100kb deletions or duplications, known as copy number changes. Microarray is particularly suited for evaluation of fetal death because DNA can still be analyzed in macerated fetuses and nonviable tissue, two situations where culturing and karyotyping is known to have low yield. Microarray has already proven successful in providing additional genetic information beyond karyotype in spontaneous abortion. The few studies on the use of microarray in stillbirth evaluation have been promising, demonstrating an increase in the diagnosis of clinically relevant genetic abnormalities when compared with karyotype. As the cost and technology improve, microarray may ultimately become the first line screen for genetic abnormalities in stillbirth. The accurate diagnosis of a genetic abnormality as the cause for fetal death may provide closure for families, prevent unnecessary treatments, and enable clinicians to more accurately counsel and manage subsequent pregnancies.

AB - Fetal death occurs in 15% of clinically recognized pregnancies. Cytogenetic abnormalities are present in 50% of spontaneous abortions (fetal deaths<20weeks) whereas the rate is 6% to 13% for stillbirths (fetal deaths≥20weeks). Microarray has been demonstrated to increase the diagnosis of genetic abnormalities by providing coverage of the entire genome at a higher density, detecting as small as 50 to 100kb deletions or duplications, known as copy number changes. Microarray is particularly suited for evaluation of fetal death because DNA can still be analyzed in macerated fetuses and nonviable tissue, two situations where culturing and karyotyping is known to have low yield. Microarray has already proven successful in providing additional genetic information beyond karyotype in spontaneous abortion. The few studies on the use of microarray in stillbirth evaluation have been promising, demonstrating an increase in the diagnosis of clinically relevant genetic abnormalities when compared with karyotype. As the cost and technology improve, microarray may ultimately become the first line screen for genetic abnormalities in stillbirth. The accurate diagnosis of a genetic abnormality as the cause for fetal death may provide closure for families, prevent unnecessary treatments, and enable clinicians to more accurately counsel and manage subsequent pregnancies.

KW - Array CGH

KW - Fetal death

KW - Fetal demise

KW - General cytogenetics

KW - Spontaneous abortion

KW - Stillbirth

UR - http://www.scopus.com/inward/record.url?scp=84859117253&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859117253&partnerID=8YFLogxK

U2 - 10.1002/pd.3825

DO - 10.1002/pd.3825

M3 - Article

VL - 32

SP - 371

EP - 375

JO - Prenatal Diagnosis

JF - Prenatal Diagnosis

SN - 0197-3851

IS - 4

ER -